

# Javier P Gisbert

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8181711/javier-p-gisbert-publications-by-citations.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

417  
papers

19,074  
citations

72  
h-index

125  
g-index

526  
ext. papers

23,761  
ext. citations

3.5  
avg, IF

7.04  
L-index

#	Paper	IF	Citations
4 <sup>17</sup>	Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. <i>Gut</i> , <b>2012</b> , 61, 646-64	19.2	1615
4 <sup>16</sup>	Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. <i>Gut</i> , <b>2017</b> , 66, 6-30	19.2	1488
4 <sup>15</sup>	Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 760-7	0.7	486
4 <sup>14</sup>	The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. <i>Gastroenterology</i> , <b>2016</b> , 151, 51-69.e14	13.3	443
4 <sup>13</sup>	Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. <i>Lancet, The</i> , <b>2012</b> , 380, 1909-15	4.0	394
4 <sup>12</sup>	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, 4-22	1.5	320
4 <sup>11</sup>	European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. <i>Journal of Crohns and Colitis</i> , <b>2015</b> , 9, 211-22	1.5	278
4 <sup>10</sup>	Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 23, 35-44	6.1	248
4 <sup>09</sup>	Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 847-58.e4; quiz e48-50	6.9	246
4 <sup>08</sup>	Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection -- a critical review. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 20, 1001-17	6.1	237
4 <sup>07</sup>	Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. <i>Inflammatory Bowel Diseases</i> , <b>2009</b> , 15, 1190-8	4.5	222
4 <sup>06</sup>	Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 1404-10	4.5	190
4 <sup>05</sup>	Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 613-23	6.1	184
4 <sup>04</sup>	Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 1921-30	0.7	183
4 <sup>03</sup>	Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 1783-800	0.7	180
4 <sup>02</sup>	Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 645-59	6.1	169
4 <sup>01</sup>	A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxicillin for treating Helicobacter pylori infection. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2000</b> , 14, 603-9	6.1	168

400	Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , <b>2009</b> , 41, 56-66	3.3	166
399	Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2002</b> , 16, 1047-57	6.1	160
398	Sequential therapy for Helicobacter pylori eradication: a critical review. <i>Journal of Clinical Gastroenterology</i> , <b>2010</b> , 44, 313-25	3	159
397	Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2005</b> , 21, 1411-8	6.1	159
396	Safety of thiopurines and anti-TNF- $\alpha$ drugs during pregnancy in patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, 433-40	0.7	157
395	Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 848-63	0.7	154
394	Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. <i>American Journal of Gastroenterology</i> , <b>2007</b> , 102, 1518-27	0.7	153
393	Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. <i>Gastroenterology</i> , <b>2013</b> , 145, 121-128.e1	13.3	152
392	Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 30, 126-37	6.1	152
391	Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 1299-307	0.7	151
390	5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. <i>Inflammatory Bowel Diseases</i> , <b>2007</b> , 13, 629-38	4.5	144
389	Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 209-21	6.1	132
388	Proton pump inhibitor, clarithromycin and either amoxicillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2000</b> , 14, 1319-28	6.1	129
387	Anemia and inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , <b>2009</b> , 15, 4659-65	5.6	127
386	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, 155-168	1.5	122
385	Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?. <i>Journal of Crohns and Colitis</i> , <b>2010</b> , 4, 144-52	1.5	119
384	Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. <i>Journal of Hepatology</i> , <b>2003</b> , 39, 620-7	13.4	119
383	Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 34, 604-17	6.1	116

382	Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 1662-9	4.5	113
381	Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 414-25	6.1	111
380	Systematic review with meta-analysis: inflammatory bowel disease in the elderly. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 459-77	6.1	105
379	Selective Manipulation of the Gut Microbiota Improves Immune Status in Vertebrates. <i>Frontiers in Immunology</i> , <b>2015</b> , 6, 512	8.4	101
378	Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 2026-33	4.5	100
377	Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. <i>Inflammatory Bowel Diseases</i> , <b>2010</b> , 16, 881-95	4.5	100
376	Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 19, 617-29	6.1	100
375	The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, 632-47	0.7	99
374	Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 1460-6	0.7	98
373	Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. <i>Clinical and Experimental Gastroenterology</i> , <b>2012</b> , 5, 23-34	3.1	98
372	Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. <i>Gut</i> , <b>2014</b> , 63, 244-9	19.2	97
371	Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response. <i>Journal of Clinical Gastroenterology</i> , <b>2011</b> , 45, 113-8	3	97
370	Long-Term Safety of In Utero Exposure to Anti-TNF Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 396-403	0.7	92
369	Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, 1426-38	0.7	88
368	Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 34, 1255-68	6.1	88
367	Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. <i>Inflammatory Bowel Diseases</i> , <b>2009</b> , 15, 1485-91	4.5	88
366	Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. <i>Inflammatory Bowel Diseases</i> , <b>2007</b> , 13, 1106-14	4.5	88
365	Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 2769-76	0.7	88

364	The stool antigen test for detection of <i>Helicobacter pylori</i> after eradication therapy. <i>Annals of Internal Medicine</i> , <b>2002</b> , 136, 280-7	8	88
363	Microbiota Sensing by Mincle-Syk Axis in Dendritic Cells Regulates Interleukin-17 and -22 Production and Promotes Intestinal Barrier Integrity. <i>Immunity</i> , <b>2019</b> , 50, 446-461.e9	32.3	87
362	Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 33, 619-33	6.1	87
361	Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. <i>Gut</i> , <b>2018</b> , 67, 237-243	19.2	84
360	Single vs. double dose of a proton pump inhibitor in triple therapy for <i>Helicobacter pylori</i> eradication: a meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2002</b> , 16, 1149-56	6.1	84
359	European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , <b>2018</b> , 12, 17-31	1.5	83
358	Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 275-83	6.1	83
357	Review article: <i>Helicobacter pylori</i> -negative duodenal ulcer disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 30, 791-815	6.1	83
356	Third-line rescue therapy with levofloxacin after two <i>H. pylori</i> treatment failures. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 243-7	0.7	83
355	Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for <i>Helicobacter pylori</i> infection. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 2447-55	5.1	82
354	"Rescue" regimens after <i>Helicobacter pylori</i> treatment failure. <i>World Journal of Gastroenterology</i> , <b>2008</b> , 14, 5385-402	5.6	82
353	Optimum duration of regimens for <i>Helicobacter pylori</i> eradication. <i>The Cochrane Library</i> , <b>2013</b> , CD008333	7.2	80
352	'Rescue' therapy with rifabutin after multiple <i>Helicobacter pylori</i> treatment failures. <i>Helicobacter</i> , <b>2003</b> , 8, 90-4	4.9	80
351	IV Spanish Consensus Conference on <i>Helicobacter pylori</i> infection treatment. <i>Gastroenterología Y Hepatología</i> , <b>2016</b> , 39, 697-721	0.9	80
350	<i>Helicobacter pylori</i> "rescue" therapy after failure of two eradication treatments. <i>Helicobacter</i> , <b>2005</b> , 10, 363-72	4.9	78
349	Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for <i>Helicobacter pylori</i> eradication. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 28, 868-77	6.1	77
348	Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 33, 340-8	6.1	76
347	<i>Helicobacter pylori</i> second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 768-75	6.1	72

346	Prevalence of Malnutrition and Nutritional Characteristics of Patients With Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , <b>2017</b> , 11, 1430-1439	1.5	72
345	Systematic review: antibodies and anti-TNF- $\beta$ levels in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 971-86	6.1	72
344	Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 391-405	6.1	68
343	Thiopurine methyltransferase activity in Spain: a study of 14,545 patients. <i>Digestive Diseases and Sciences</i> , <b>2007</b> , 52, 1262-9	4	67
342	Urine metabolome profiling of immune-mediated inflammatory diseases. <i>BMC Medicine</i> , <b>2016</b> , 14, 133	11.4	67
341	Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 120-131	0.7	66
340	Systematic review: gastric microbiota in health and disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 582-602	6.1	66
339	Delphi consensus statement: Quality Indicators for Inflammatory Bowel Disease Comprehensive Care Units. <i>Journal of Crohns and Colitis</i> , <b>2014</b> , 8, 240-51	1.5	65
338	Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence. <i>International Journal of Cancer</i> , <b>2013</b> , 133, 1023-32	7.5	65
337	Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 71-6	0.7	65
336	Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible <i>Helicobacter pylori</i> and versus sequential therapy for clarithromycin-resistant strains. <i>Helicobacter</i> , <b>2012</b> , 17, 269-76	4.9	64
335	Empirical rescue therapy after <i>Helicobacter pylori</i> treatment failure: a 10-year single-centre study of 500 patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 27, 346-54	6.1	64
334	Seven-day 'rescue' therapy after <i>Helicobacter pylori</i> treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. <i>Alimentary Pharmacology and Therapeutics</i> , <b>1999</b> , 13, 1311-6	6.1	64
333	Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 953-8	4	62
332	Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 1379-85	6.1	62
331	A review of rescue regimens after clarithromycin-containing triple therapy failure (for <i>Helicobacter pylori</i> eradication). <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 843-61	4	62
330	Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two <i>Helicobacter pylori</i> treatment failures. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 24, 1469-74	6.1	62
329	Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. <i>Journal of Crohns and Colitis</i> , <b>2013</b> , 7, 717-22	1.5	61



328	Epidemiological risk factors in microscopic colitis: a prospective case-control study. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 411-7	4.5	61
327	Has H. pylori prevalence in bleeding peptic ulcer been underestimated? A meta-regression. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106, 398-405	0.7	60
326	Evolution of Helicobacter pylori therapy from a meta-analytical perspective. <i>Helicobacter</i> , <b>2007</b> , 12 Suppl 2, 50-8	4.9	60
325	Smoking does influence disease behaviour and impacts the need for therapy in Crohn's disease in the biologic era. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 752-60	6.1	58
324	Human intestinal pro-inflammatory CD11cCCR2CX3CR1 macrophages, but not their tolerogenic CD11cCCR2CX3CR1 counterparts, are expanded in inflammatory bowel disease. <i>Mucosal Immunology</i> , <b>2018</b> , 11, 1114-1126	9.2	56
323	The association between Helicobacter pylori infection and inflammatory bowel disease based on meta-analysis. <i>United European Gastroenterology Journal</i> , <b>2015</b> , 3, 539-50	5.3	54
322	Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 581-9	6.1	54
321	Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, 694-709	1.5	54
320	Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 839-851	6.1	53
319	Long-term follow-up of 1,000 patients cured of Helicobacter pylori infection following an episode of peptic ulcer bleeding. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 1197-204	0.7	51
318	Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients. <i>Journal of Clinical Gastroenterology</i> , <b>2013</b> , 47, 130-5	3	51
317	Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 941-7	6.1	50
316	Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 10338-47	5.6	48
315	Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 1394-1402	4.5	47
314	Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational study. <i>Health and Quality of Life Outcomes</i> , <b>2009</b> , 7, 90	3	47
313	Effectiveness of adalimumab in perianal fistulas in crohn's disease patients naive to anti-TNF therapy. <i>Journal of Clinical Gastroenterology</i> , <b>2015</b> , 49, 34-40	3	46
312	Impact of current smoking on the clinical course of microscopic colitis. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 1470-6	4.5	45
311	First-line triple therapy with levofloxacin for Helicobacter pylori eradication. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 26, 495-500	6.1	44

310	Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2005</b> , 22, 1041-6	6.1	44
309	Accuracy of GastroPanel for the diagnosis of atrophic gastritis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2014</b> , 26, 941-8	2.2	43
308	Long-term durability of response to adalimumab in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 685-90	4.5	43
307	Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 287-90	3.3	43
306	Treatment of Helicobacter pylori infection 2013. <i>Helicobacter</i> , <b>2013</b> , 18 Suppl 1, 58-65	4.9	41
305	European Registry on management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. <i>Gut</i> , <b>2021</b> , 70, 40-54	19.2	41
304	Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. <i>Helicobacter</i> , <b>2017</b> , 22, e12392	4.9	40
303	Recurrence of Helicobacter pylori infection after eradication: incidence and variables influencing it. <i>Scandinavian Journal of Gastroenterology</i> , <b>1998</b> , 33, 1144-51	2.4	40
302	Identification of risk loci for Crohn's disease phenotypes using a genome-wide association study. <i>Gastroenterology</i> , <b>2015</b> , 148, 794-805	13.3	39
301	Review article: common misconceptions in the management of Helicobacter pylori-associated gastric MALT-lymphoma. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 34, 1047-62	6.1	39
300	Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish Microscopic Colitis Group. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 400-26	6.1	39
299	Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 605-614	6.1	38
298	Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection. <i>Digestive Diseases and Sciences</i> , <b>2014</b> , 59, 383-9	4	37
297	Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy. <i>Digestive Diseases and Sciences</i> , <b>2015</b> , 60, 458-64	4	36
296	Thiopurine Therapy Reduces the Incidence of Colorectal Neoplasia in Patients with Ulcerative Colitis. Data from the ENEIDA Registry. <i>Journal of Crohns and Colitis</i> , <b>2015</b> , 9, 1063-70	1.5	36
295	Helicobacter Pylori "Test-and-Treat" Strategy for Management of Dyspepsia: A Comprehensive Review. <i>Clinical and Translational Gastroenterology</i> , <b>2013</b> , 4, e32	4.2	35
294	Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 11273-81	5.6	35
293	Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab. <i>Human Immunology</i> , <b>2014</b> , 75, 71-5	2.3	33



292	Role of partner's infection in reinfection after <i>Helicobacter pylori</i> eradication. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2002</b> , 14, 865-71	2.2	33
291	Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 278-288	6.1	32
290	Intensification of infliximab therapy in Crohn's disease: efficacy and safety. <i>Journal of Crohns and Colitis</i> , <b>2012</b> , 6, 62-7	1.5	32
289	Evaluation of three different tests for the detection of stool antigens to diagnose <i>Helicobacter pylori</i> infection in patients with upper gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 19, 923-9	6.1	32
288	Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease. <i>Current Pharmaceutical Biotechnology</i> , <b>2011</b> , 12, 765-73	2.6	32
287	Combination of Bismuth and Standard Triple Therapy Eradicates <i>Helicobacter pylori</i> Infection in More than 90% of Patients. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 89-98	6.9	32
286	Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation. <i>Digestive Diseases and Sciences</i> , <b>2017</b> , 62, 481-490	4	31
285	Role of food proteins and bioactive peptides in inflammatory bowel disease. <i>Trends in Food Science and Technology</i> , <b>2019</b> , 88, 194-206	15.3	31
284	A genome-wide association study identifies a novel locus at 6q22.1 associated with ulcerative colitis. <i>Human Molecular Genetics</i> , <b>2014</b> , 23, 6927-34	5.6	31
283	Current management of iron deficiency anemia in inflammatory bowel diseases: a practical guide. <i>Drugs</i> , <b>2013</b> , 73, 1761-70	12.1	31
282	Rescue Therapy for <i>Helicobacter pylori</i> Infection 2012. <i>Gastroenterology Research and Practice</i> , <b>2012</b> , 2012, 974594	2	31
281	Triple vs quadruple therapy for treating <i>Helicobacter pylori</i> infection: an updated meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2003</b> , 18, 543-4	6.1	31
280	Treatment of <i>Helicobacter pylori</i> infection in 2018. <i>Helicobacter</i> , <b>2018</b> , 23 Suppl 1, e12519	4.9	31
279	Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn's and Colitis Organisation [ECCO] Position Paper. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, 1037-1048	1.5	30
278	<i>Helicobacter pylori</i> infection does not protect against eosinophilic esophagitis: results from a large multicenter case-control study. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 972-979	0.7	30
277	<i>Propionibacterium acnes</i> overabundance and natural killer group 2 member D system activation in corpus-dominant lymphocytic gastritis. <i>Journal of Pathology</i> , <b>2016</b> , 240, 425-436	9.4	30
276	Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, 261-8	0.7	30
275	Intestinal microbiota and colorectal carcinoma: Implications for pathogenesis, diagnosis, and therapy. <i>EBioMedicine</i> , <b>2019</b> , 48, 648-655	8.8	30

274	Kinetics of anti-hepatitis B surface antigen titers after hepatitis B vaccination in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 554-8	4.5	30
273	The TETRA study: a prospective evaluation of Helicobacter pylori 'test-and-treat' strategy on 736 patients in clinical practice. <i>Helicobacter</i> , <b>2004</b> , 9, 28-38	4.9	30
272	Hepatocellular carcinoma risk in patients with porphyria cutanea tarda. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2004</b> , 16, 689-92	2.2	30
271	Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment?. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, 1935-40	6.7	30
270	Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus. <i>Digestive Diseases</i> , <b>2019</b> , 37, 266-283	3.2	29
269	Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori. <i>Helicobacter</i> , <b>2019</b> , 24, e12570	4.9	29
268	Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3). <i>Journal of Crohns and Colitis</i> , <b>2014</b> , 8, 1529-38	1.5	28
267	The Innate Immune System in the Gastrointestinal Tract: Role of Intraepithelial Lymphocytes and Lamina Propria Innate Lymphoid Cells in Intestinal Inflammation. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 1649-1659	4.5	28
266	Treatment of Helicobacter pylori infection 2012. <i>Helicobacter</i> , <b>2012</b> , 17 Suppl 1, 36-42	4.9	27
265	Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: a real-life survey in Spain. <i>Journal of Crohns and Colitis</i> , <b>2010</b> , 4, 567-74	1.5	27
264	Treatment of Helicobacter pylori Infection 2015. <i>Helicobacter</i> , <b>2015</b> , 20 Suppl 1, 54-61	4.9	26
263	Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU. <i>Gastroenterología Y Hepatología</i> , <b>2013</b> , 36, 104-14	0.9	25
262	Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection. <i>Scandinavian Journal of Gastroenterology</i> , <b>2013</b> , 48, 652-6	2.4	25
261	Prevalence and Factors Associated With Fatigue in Patients With Inflammatory Bowel Disease: A Multicentre Study. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, 996-1002	1.5	24
260	Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, 1492-1500	1.5	24
259	Human Intestinal Dendritic Cells in Inflammatory Bowel Diseases. <i>Molecular Nutrition and Food Research</i> , <b>2018</b> , 62, e1700931	5.9	24
258	Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 592-600	3.3	24
257	Angiopoietins in inflammation and their implication in the development of inflammatory bowel disease. A review. <i>Journal of Crohns and Colitis</i> , <b>2014</b> , 8, 183-90	1.5	24

256	High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high <i>Helicobacter pylori</i> eradication rates. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 190-6	6.1	24
255	Health care costs of complex perianal fistula in Crohn's disease. <i>Digestive Diseases and Sciences</i> , <b>2013</b> , 58, 3400-6	4	24
254	Systematic review: Rabeprazole-based therapies in <i>Helicobacter pylori</i> eradication. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2003</b> , 17, 751-64	6.1	24
253	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease. <i>Gastroenterología Y Hepatología</i> , <b>2018</b> , 41, 205-221	0.9	23
252	Systematic review: third-line susceptibility-guided treatment for <i>Helicobacter pylori</i> infection. <i>Therapeutic Advances in Gastroenterology</i> , <b>2016</b> , 9, 437-48	4.7	23
251	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. <i>Gastroenterología Y Hepatología</i> , <b>2018</b> , 41, 514-529	0.9	23
250	'Quality of Care' Standards in Inflammatory Bowel Disease: A Systematic Review. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, 127-137	1.5	23
249	Protocol of the European Registry on the management of <i>Helicobacter pylori</i> infection (Hp-EuReg). <i>Helicobacter</i> , <b>2019</b> , 24, e12630	4.9	22
248	Review: Treatment of <i>Helicobacter pylori</i> Infection 2019. <i>Helicobacter</i> , <b>2019</b> , 24 Suppl 1, e12640	4.9	22
247	Risk of colectomy in patients with ulcerative colitis under thiopurine treatment. <i>Journal of Crohns and Colitis</i> , <b>2014</b> , 8, 1287-93	1.5	22
246	Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience. <i>Gastroenterología Y Hepatología</i> , <b>2011</b> , 34, 443-8	0.9	22
245	Effectiveness of infliximab after adalimumab failure in Crohn's disease. <i>World Journal of Gastroenterology</i> , <b>2012</b> , 18, 5219-24	5.6	22
244	Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , <b>2015</b> , 60, 3075-84	4	21
243	Endothelial MT1-MMP targeting limits intussusceptive angiogenesis and colitis via TSP1/nitric oxide axis. <i>EMBO Molecular Medicine</i> , <b>2020</b> , 12, e10862	12	21
242	Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for <i>Helicobacter pylori</i> first-line treatment. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 2740-53	5.1	21
241	Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 601-7	3.3	21
240	Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response. <i>Gastroenterología Y Hepatología</i> , <b>2008</b> , 31, 421-6	0.9	21
239	Eradication of <i>Helicobacter pylori</i> for the prevention of peptic ulcer rebleeding. <i>Helicobacter</i> , <b>2007</b> , 12, 279-86	4.9	21

238	13C-urea breath test during hospitalization for the diagnosis of <i>Helicobacter pylori</i> infection in peptic ulcer bleeding. <i>Helicobacter</i> , <b>2007</b> , 12, 231-7	4.9	21
237	The prevalence of hepatitis C virus infection in patients with non-Hodgkin's lymphoma. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2004</b> , 16, 135-8	2.2	21
236	Systematic Review: The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease. <i>Microorganisms</i> , <b>2021</b> , 9,	4.9	21
235	Increased risk of thiopurine-related adverse events in elderly patients with IBD. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 780-788	6.1	20
234	Acute severe ulcerative colitis: State of the art treatment. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2018</b> , 32-33, 59-69	2.5	20
233	Ratio of Circulating Estrogen Receptors Beta and Alpha (ER $\beta$ /ER $\alpha$ ) Indicates Endoscopic Activity in Patients with Crohn's Disease. <i>Digestive Diseases and Sciences</i> , <b>2017</b> , 62, 2744-2754	4	20
232	Pantoprazole based therapies in <i>Helicobacter pylori</i> eradication: a systematic review and meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2004</b> , 16, 89-99	2.2	20
231	Clinical Usefulness of Proteomics in Inflammatory Bowel Disease: A Comprehensive Review. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, 374-384	1.5	20
230	Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, 606-616	4.5	19
229	Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 353-359	3.3	19
228	Sequential versus standard triple first-line therapy for <i>Helicobacter pylori</i> eradication. <i>The Cochrane Library</i> , <b>2016</b> , CD009034	5.2	19
227	Empirical <i>Helicobacter pylori</i> "rescue" therapy after failure of two eradication treatments. <i>Digestive and Liver Disease</i> , <b>2004</b> , 36, 7-12	3.3	19
226	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. <i>Journal of Crohns and Colitis</i> , <b>2021</b> ,	1.5	19
225	A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent infection. <i>United European Gastroenterology Journal</i> , <b>2019</b> , 7, 1051-1063	5.3	18
224	Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?. <i>Scandinavian Journal of Gastroenterology</i> , <b>2015</b> , 50, 379-86	2.4	18
223	Phenotypic concordance in familial inflammatory bowel disease (IBD). Results of a nationwide IBD Spanish database. <i>Journal of Crohns and Colitis</i> , <b>2014</b> , 8, 654-61	1.5	18
222	Letter: third-line rescue therapy with levofloxacin after failure of two treatments to eradicate <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 1484-5; author reply 1486	6.1	18
221	Treatment of <i>Helicobacter pylori</i> infection 2017. <i>Helicobacter</i> , <b>2017</b> , 22 Suppl 1, e12410	4.9	18

220	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the monitoring, prevention and treatment of post-operative recurrence in Crohn's disease. <i>Gastroenterología Y Hepatología</i> , <b>2017</b> , 40, 472-483	0.9	18
219	Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 108-13	3.3	18
218	Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 419-428	6.1	18
217	Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	17
216	Outcomes of Medical and Surgical Therapy for Entero-urinary Fistulas in Crohn's Disease. <i>Journal of Crohns and Colitis</i> , <b>2016</b> , 10, 657-62	1.5	17
215	Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for Helicobacter pylori therapy: A randomized, double-blind, placebo-controlled trial. <i>Helicobacter</i> , <b>2018</b> , 23, e12529	4.9	17
214	Prevalence of Helicobacter pylori infection in medical professionals in Spain. <i>European Journal of Gastroenterology and Hepatology</i> , <b>1999</b> , 11, 239-42	2.2	17
213	Monitoring thiopurine metabolites in inflammatory bowel disease. <i>Frontline Gastroenterology</i> , <b>2016</b> , 7, 301-307	2.6	17
212	Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review. <i>Gastroenterología Y Hepatología</i> , <b>2018</b> , 41, 389-405	0.9	17
211	Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis. <i>Drugs</i> , <b>2017</b> , 77, 765-776	12.1	16
210	Review article: is there an optimal therapeutic regimen for antimicrobial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2003</b> , 17, 17-27	6.1	16
209	Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1135-1143	0.7	15
208	Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H. pylori management (Hp-EuReg). <i>Helicobacter</i> , <b>2020</b> , 25, e12686	4.9	15
207	Immunomodulatory Effect of Gut Microbiota-Derived Bioactive Peptides on Human Immune System from Healthy Controls and Patients with Inflammatory Bowel Disease. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	15
206	Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 1086-1091	3.3	15
205	Is culture necessary before first-line treatment for Helicobacter pylori infection?. <i>Internal Medicine</i> , <b>2011</b> , 50, 2717; author reply 2719-20	1.1	15
204	Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 1220-1229	0.7	15
203	Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 846-854	4	15



202	Collagenous colitis: Requirement for high-dose budesonide as maintenance treatment. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 973-977	3.3	14
201	Effectiveness and Safety of the Switch from Remicade <sup>®</sup> to CT-P13 in Patients with Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, 1380-1386	1.5	14
200	Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile. <i>Mediators of Inflammation</i> , <b>2015</b> , 2015, 318207	4.3	14
199	Helicobacter pylori test-and-treat' strategy for dyspeptic patients. <i>Scandinavian Journal of Gastroenterology</i> , <b>1999</b> , 34, 644-52	2.4	14
198	Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. <i>Gastroenterology</i> , <b>2021</b> , 161, 495-507.e4	13.3	14
197	Helicobacter pylori and gastroesophageal reflux disease: friends or foes?. <i>Hepato-Gastroenterology</i> , <b>1999</b> , 46, 1023-9		14
196	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients. <i>Gastroenterología Y Hepatología</i> , <b>2018</b> , 41, 118-127	0.9	13
195	Maintenance therapy options for ulcerative colitis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 1339-42		13
194	Evaluation of 3 different tests for the detection of stool antigens to confirm Helicobacter pylori eradication after treatment. A pilot study. <i>Gastroenterología Y Hepatología</i> , <b>2005</b> , 28, 615-8	0.9	13
193	Gene expression study and pathway analysis of histological subtypes of intestinal metaplasia that progress to gastric cancer. <i>PLoS ONE</i> , <b>2017</b> , 12, e0176043	3.7	13
192	Empirical or susceptibility-guided treatment for infection? A comprehensive review. <i>Therapeutic Advances in Gastroenterology</i> , <b>2020</b> , 13, 1756284820968736	4.7	13
191	Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry. <i>Journal of Crohns and Colitis</i> , <b>2021</b> , 15, 35-42	1.5	13
190	Efficacy of tofacitinib treatment in ulcerative colitis. <i>Gastroenterología Y Hepatología</i> , <b>2019</b> , 42, 403-412	0.9	12
189	Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review. <i>Drugs</i> , <b>2020</b> , 80, 1085-1100	12.1	12
188	Helicobacter pylori "Test-and-Treat" strategy with urea breath test: A cost-effective strategy for the management of dyspepsia and the prevention of ulcer and gastric cancer in Spain-Results of the Hp-Breath initiative. <i>Helicobacter</i> , <b>2020</b> , 25, e12693	4.9	12
187	Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , <b>2018</b> , 12, 1270-1279	1.5	12
186	Risk assessment and outpatient management in bleeding peptic ulcer. <i>Journal of Clinical Gastroenterology</i> , <b>2006</b> , 40, 129-34	3	12
185	The Interplay between Immune System and Microbiota in Inflammatory Bowel Disease: A Narrative Review. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	12



184	Systematic review with meta-analysis: the prevalence of bile acid malabsorption and response to colestyramine in patients with chronic watery diarrhoea and previous cholecystectomy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 242-250	6.1	12
183	<i>Helicobacter pylori</i> inactivation and virulence gene damage using a supported sensitiser for photodynamic therapy. <i>European Journal of Medicinal Chemistry</i> , <b>2013</b> , 68, 284-90	6.8	11
182	Research to the N-Power: The Strengths of Networked Clinical Collaboration in Spain. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1761-1764	0.7	11
181	Infliximab therapy reverses the increase of allograft inflammatory factor-1 in serum and colonic mucosa of rats with inflammatory bowel disease. <i>Biomarkers</i> , <b>2017</b> , 22, 133-144	2.6	11
180	Management of gastro-oesophageal reflux disease in primary care: a European observational study. <i>Current Medical Research and Opinion</i> , <b>2009</b> , 25, 2777-84	2.5	11
179	Rifaximin for the Treatment of Infection: A Review. <i>Pathogens</i> , <b>2020</b> , 10,	4.5	11
178	The Role of Immunomodulators and Biologics in the Medical Management of Strictureing Crohn's Disease. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, 557-566	1.5	11
177	Spanish primary care survey on the management of <i>Helicobacter pylori</i> infection and dyspepsia: Information, attitudes, and decisions. <i>Helicobacter</i> , <b>2019</b> , 24, e12593	4.9	10
176	Treatment of <i>Helicobacter pylori</i> infection 2016. <i>Helicobacter</i> , <b>2016</b> , 21 Suppl 1, 55-61	4.9	10
175	How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease?. <i>Expert Opinion on Drug Safety</i> , <b>2014</b> , 13, 1749-62	4.1	10
174	Adalimumab-induced interstitial pneumonia in a patient with Crohn's disease. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 2260-2	5.6	10
173	Poor Sensitivity of Fecal Gluten Immunogenic Peptides and Serum Antibodies to Detect Duodenal Mucosal Damage in Celiac Disease Monitoring. <i>Nutrients</i> , <b>2020</b> , 13,	6.7	10
172	Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic strictureing Crohn's disease. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 1056-1066	5.3	10
171	Pyrrolidinium-type fullerene derivative-induced apoptosis by the generation of reactive oxygen species in HL-60 cells. <i>European Journal of General Practice</i> , <b>2009</b> , 43, 1240-7	2.8	10
170	Biosimilar and interchangeable: Inseparable scientific concepts?. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 2460-2463	3.8	9
169	Epidemiology: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain. <i>Therapeutic Advances in Gastroenterology</i> , <b>2019</b> , 12, 1756284819847034	4.7	9
168	Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 2080-2087	4	9
167	Effectiveness of anti-TNF $\alpha$ drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNF $\alpha$ agent. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 613-9	3.3	9

166	7-day rescue therapy with ranitidine bismuth citrate after <i>Helicobacter pylori</i> treatment failure. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2005</b> , 21, 1249-53	6.1	9
165	Gastric MALT lymphoma: clinical characteristics and prevalence of <i>H. pylori</i> infection in a series of 37 cases. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2006</b> , 98, 655-65	0.9	9
164	Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab. <i>Biochemical Pharmacology</i> , <b>2016</b> , 122, 33-41	6	9
163	Room for Improvement in the Treatment of <i>Helicobacter pylori</i> Infection: Lessons from the European Registry on <i>H. pylori</i> Management (Hp-EuReg). <i>Journal of Clinical Gastroenterology</i> , <b>2021</b> , Publish Ahead of Print,	3	9
162	Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. <i>Cell Host and Microbe</i> , <b>2021</b> , 29, 1573-1588.e7	23.4	9
161	Accuracy of the Ultra-Rapid Urease Test for diagnosis of <i>Helicobacter pylori</i> infection. <i>Gastroenterología Y Hepatología</i> , <b>2017</b> , 40, 651-657	0.9	8
160	Ustekinumab to treat Crohn's disease. <i>Gastroenterología Y Hepatología</i> , <b>2017</b> , 40, 688-698	0.9	8
159	Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for <i>H. pylori</i> eradication: A phase IV pilot clinical trial. <i>Gastroenterología Y Hepatología</i> , <b>2017</b> , 40, 658-662	0.9	8
158	Letter: are lymphocytic colitis and collagenous colitis really the same disease?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 606	6.1	8
157	Review - Treatment of <i>Helicobacter pylori</i> infection 2020. <i>Helicobacter</i> , <b>2020</b> , 25 Suppl 1, e12743	4.9	8
156	The ENEIDA registry (Nationwide study on genetic and environmental determinants of inflammatory bowel disease) by GETECCU: Design, monitoring and functions. <i>Gastroenterología Y Hepatología</i> , <b>2020</b> , 43, 551-558	0.9	8
155	Peptides encrypted in the human intestinal microbial-exoproteome as novel biomarkers and immunomodulatory compounds in the gastrointestinal tract. <i>Journal of Functional Foods</i> , <b>2019</b> , 52, 459-468	5.1	8
154	Randomised clinical trial: intravenous vs oral iron for the treatment of anaemia after acute gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 258-268	6.1	7
153	Recommendations of the Crohn's Disease and Ulcerative Colitis Spanish Working Group (GETECCU) for the treatment of perianal fistulas of Crohn's disease. <i>Gastroenterología Y Hepatología</i> , <b>2020</b> , 43, 155-168	1.9	7
152	Update on the management of <i>Helicobacter pylori</i> infection. Position paper from the Catalan Society of Digestology. <i>Gastroenterología Y Hepatología</i> , <b>2018</b> , 41, 272-280	0.9	7
151	Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for <i>Helicobacter pylori</i> infection. <i>International Journal of Clinical Practice</i> , <b>2017</b> , 71, e13004	2.9	7
150	Consultation rates and characteristics of gastro-oesophageal reflux disease in primary care: a European observational study. <i>European Journal of General Practice</i> , <b>2009</b> , 15, 154-60	2.8	7
149	Etolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> ,	18.8	7

148	Empirical <i>Helicobacter pylori</i> rescue therapy: an 18-year single-centre study of 1200 patients. <i>GastroHep</i> , <b>2019</b> , 1, 311-324	1	7
147	Management of acute severe ulcerative colitis in Spain: A nationwide clinical practice survey. <i>Gastroenterología Y Hepatología</i> , <b>2019</b> , 42, 90-101	0.9	7
146	Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. <i>Hepato-Gastroenterology</i> , <b>2006</b> , 53, 399-404		7
145	Mentor-mentee relationship in medicine. <i>Gastroenterología Y Hepatología</i> , <b>2017</b> , 40, 48-57	0.9	6
144	Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 766	5.3	6
143	Efficacy and safety of vedolizumab in the treatment of ulcerative colitis. <i>Gastroenterología Y Hepatología</i> , <b>2016</b> , 39, 677-686	0.9	6
142	Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1180-1188.e4	6.9	6
141	Validation of the 'United Registries for Clinical Assessment and Research' [UR-CARE], a European Online Registry for Clinical Care and Research in Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , <b>2018</b> , 12, 532-537	1.5	5
140	Prevalence of severe esophagitis in Spain. Results of the PRESS study (Prevalence and Risk factors for Esophagitis in Spain: A cross-sectional study). <i>United European Gastroenterology Journal</i> , <b>2016</b> , 4, 229-35	5.3	5
139	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 1: Epidemiology, diagnosis and prognosis. <i>Gastroenterología Y Hepatología</i> , <b>2019</b> , 42, 568-578	0.9	5
138	<i>Helicobacter Pylori</i> Treatment Results in Slovenia in the Period 2013-2015 as a Part of European Registry on <i>Helicobacter Pylori</i> Management. <i>Radiology and Oncology</i> , <b>2018</b> , 52, 1-6	3.8	5
137	<i>H. pylori</i> eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. <i>Cochrane Database of Systematic Reviews</i> , <b>2003</b> , CD004062		5
136	Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 1802-1811	0.7	5
135	Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for <i>Helicobacter pylori</i> infection: Spanish data of the European <i>Helicobacter pylori</i> Registry (Hp-EuReg). <i>Helicobacter</i> , <b>2020</b> , 25, e12722	4.9	5
134	Genetic variation analysis in a follow-up study of gastric cancer precursor lesions confirms the association of MUC2 variants with the evolution of the lesions and identifies a significant association with NFKB1 and CD14. <i>International Journal of Cancer</i> , <b>2018</b> , 143, 2777-2786	7.5	5
133	Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 870-879	6.1	4
132	Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, 1290-1298	1.5	4
131	Rectal hypersensitivity in patients with quiescent ulcerative colitis. <i>Journal of Crohns and Colitis</i> , <b>2015</b> , 9, 592	1.5	4

130	European Registry on the management of Helicobacter pylori infection (Hp-EuReg): Analysis of 2360 patients receiving first-line therapy in Russia. <i>Terapevticheskii Arkhiv</i> , <b>2018</b> , 90, 35-42	0.9	4
129	IV Spanish Consensus Conference on Helicobacter pylori infection treatment. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2016</b> , 39, 697-721	0.1	4
128	Protein tyrosine phosphatase nonreceptor type 2 controls colorectal cancer development. <i>Journal of Clinical Investigation</i> , <b>2021</b> , 131,	15.9	4
127	Gut Microbiota and Dietary Factors as Modulators of the Mucus Layer in Inflammatory Bowel Disease. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	4
126	Letter: the definition of budesonide dependence in microscopic colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 635	6.1	3
125	Optimization Strategies Aimed to Increase the Efficacy of Eradication Therapies with Quinolones. <i>Molecules</i> , <b>2020</b> , 25,	4.8	3
124	P744 Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): Results from the nationwide EpidemIBD study of GETECCU. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, S594-S597	1.5	3
123	Open questions and misconceptions in the diagnosis and management of anemia in patients with gastrointestinal bleeding. <i>Gastroenterología Y Hepatología</i> , <b>2018</b> , 41, 63-76	0.9	3
122	Outcome after a dose "de-intensification" strategy with anti-TNF drugs in patients with Crohn's disease. <i>Gastroenterología Y Hepatología</i> , <b>2016</b> , 39, 255-60	0.9	3
121	Commentary: comparators in H. pylori eradication--stating the ethics of statins. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 400-1	6.1	3
120	V Spanish Consensus Conference on Helicobacter pylori infection treatment. <i>Gastroenterología Y Hepatología</i> , <b>2021</b> ,	0.9	3
119	Tips and guidelines for being a successful researcher. <i>Gastroenterología Y Hepatología</i> , <b>2020</b> , 43, 540-550	0.9	3
118	Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry. <i>Journal of Crohns and Colitis</i> , <b>2021</b> , 15, 1846-1851	1.5	3
117	Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	3
116	Helicobacter pylori-related diseases. <i>Gastroenterología Y Hepatología</i> , <b>2016</b> , 39 Suppl 1, 36-46	0.9	3
115	Recommendations by the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the treatment of patients with inflammatory bowel disease associated with spondyloarthritis. <i>Gastroenterología Y Hepatología</i> , <b>2020</b> , 43, 273-283	0.9	3
114	Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved. <i>Biomedicine and Pharmacotherapy</i> , <b>2021</b> , 144, 112239	7.5	3
113	Reply. <i>Gastroenterology</i> , <b>2017</b> , 152, 303-304	13.3	2

112	Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn's disease. <i>Pharmacogenomics Journal</i> , <b>2019</b> , 19, 547-555	3.5	2
111	Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 529-535	3.3	2
110	A quick flow cytometry protocol to assess Helicobacter pylori viability. <i>Journal of Microbiological Methods</i> , <b>2020</b> , 177, 106043	2.8	2
109	Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2020</b> , 32, 588-596	2.2	2
108	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2018</b> , 41, 205-221	0.1	2
107	Towards effective empirical treatment for Helicobacter pylori eradication. <i>Lancet, The</i> , <b>2016</b> , 388, 2325-2326	4.26	2
106	Warnings on the safety of quinolones: Should Helicobacter pylori treatment prescriptions be modified?. <i>Gastroenterología Y Hepatología</i> , <b>2019</b> , 42, 461-463	0.9	2
105	Optimum duration of regimens for Helicobacter pylori eradication <b>2010</b> ,		2
104	Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	2
103	Measurement of anti-TNF agents and anti-drug antibodies serum levels in patients with inflammatory bowel disease. <i>Current Drug Metabolism</i> , <b>2014</b> , 15, 875-81	3.5	2
102	European Registry on Management: Effectiveness of First and Second-Line Treatment in Spain. <i>Antibiotics</i> , <b>2020</b> , 10,	4.9	2
101	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. <i>Journal of Crohns and Colitis</i> , <b>2021</b> ,	1.5	2
100	The prevention and management of Crohn's disease postoperative recurrence: results from the Y-ECCO/ClinCom 2019 Survey. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2020</b> , 32, 1062-1066	2.2	2
99	Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	2
98	Lunasin Peptide is a Modulator of the Immune Response in the Human Gastrointestinal Tract. <i>Molecular Nutrition and Food Research</i> , <b>2021</b> , 65, e2001034	5.9	2
97	Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	2
96	Letter: Helicobacter pylori infection and eosinophilic oesophagitis - causal or casual inverse association?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 1244	6.1	2
95	European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 38-46	5.3	2



94	The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU. <i>Therapeutic Advances in Gastroenterology</i> , <b>2021</b> , 14, 17562848211018097	4.7	2
93	Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF- $\alpha$ results from the ENEIDA registry. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 1021-1029	6.1	2
92	Non-responsive coeliac disease: Coeliac crisis vs. refractory coeliac disease with response to corticosteroids. <i>Gastroenterología Y Hepatología</i> , <b>2017</b> , 40, 529-530	0.9	1
91	P424 Is the switch to a second thiopurine a safe strategy in elderly patients with inflammatory bowel disease? A multi-centre cohort study of the ENEIDA registry. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, S321-S322	1.5	1
90	Letter: Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 494-5	6.1	1
89	Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum HpSA and novel ImmunoCard STAT! rapid test) for the diagnosis of Helicobacter pylori infection. <i>Gastroenterología Y Hepatología</i> , <b>2020</b> , 43, 117-125	0.9	1
88	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment. <i>Gastroenterología Y Hepatología</i> , <b>2020</b> , 43, 649-658	0.9	1
87	Efficacy of tofacitinib treatment in ulcerative colitis. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2019</b> , 42, 403-412	0.1	1
86	Optimum second-line regimens for Helicobacter pylori eradication. <i>The Cochrane Library</i> , <b>2014</b> ,	5.2	1
85	Letter: mucosal healing in ulcerative colitis--higher relevance than in Crohn's disease?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 207	6.1	1
84	Letter: ciclosporin or infliximab in acute ulcerative colitis - still undecided. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 992	6.1	1
83	Letter: bismuth, levofloxacin, amoxicillin, PPI quadruple therapy is not an effective first or second-line regimen in the presence of levofloxacin resistance--authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 1221-2	6.1	1
82	Letter: sitafloxacin for H. pylori infection in Japan: considerations on resistance rates, generalisability and its place in the therapeutic algorithm. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 942-3	6.1	1
81	Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 940-1	6.1	1
80	Letter: acute severe ulcerative colitis - should all patients be treated equally?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 113	6.1	1
79	Letter: infliximab in severe ulcerative colitis - is it useful for all patients?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 1413	6.1	1
78	How to prepare a research proposal in the health sciences?. <i>Gastroenterología Y Hepatología</i> , <b>2021</b> , 44, 730-740	0.9	1
77	Clinical characteristics and prognostic factors for Crohn's disease relapses using natural language processing and machine learning: a pilot study. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2021</b> , 34,	2.2	1



76	Assessment of first-line eradication treatment in Greece: data from the European Registry on management (Hp-EuReg).. <i>Annals of Gastroenterology</i> , <b>2022</b> , 35, 42-47	2.2	1
75	Pericardial effusion associated with mesalamine treatment in a patient with ulcerative colitis. <i>Gastroenterología Y Hepatología</i> , <b>2021</b> , 44, 721-723	0.9	1
74	Helicobacter pylori Eradication Rates in Slovenia in the Period from 2017 to 2019: Data from the European Registry on H. pylori Management. <i>Digestive Diseases</i> , <b>2021</b> , 39, 318-324	3.2	1
73	Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 1277-1288	6.1	1
72	Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 583-98	4.5	1
71	In H. pylori- infected patients second-line treatment with sequential levofloxacin therapy was more effective than levofloxacin triple therapy but was still suboptimal. <i>Evidence-Based Medicine</i> , <b>2016</b> , 21, 144		1
70	Efficacy and safety of vedolizumab in the treatment of ulcerative colitis. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2016</b> , 39, 677-686	0.1	1
69	Open questions and misconceptions in the diagnosis and management of anemia in patients with gastrointestinal bleeding. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2018</b> , 41, 63-76	0.1	1
68	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2018</b> , 41, 514-529	0.1	1
67	Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2018</b> , 41, 389-405	0.1	1
66	Clinical features, therapeutic requirements and evolution of patients with Crohn's disease and upper gastrointestinal involvement (CROHNEX study). <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 1041-1051	6.1	1
65	Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
64	Challenges of independent clinical research. <i>Gastroenterología Y Hepatología</i> , <b>2021</b> , 44, 599-610	0.9	1
63	European Registry on Helicobacter pylori management (Hp-EuReg): First-line Therapy in Israel. <i>Israel Medical Association Journal</i> , <b>2021</b> , 23, 38-42	0.9	1
62	Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry. <i>Journal of Crohns and Colitis</i> , <b>2021</b> ,	1.5	1
61	Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series. <i>Journal of Crohns and Colitis</i> , <b>2021</b> ,	1.5	1
60	P138 Prediction model to safely cease anti-TNF therapy in Crohn's disease: individual patient data meta-analysis (IPD-MA). <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, S158-S159	1.5	0
59	Launch and preliminary analysis of Hospital de La Princesa's inter-specialists biological therapies unit. <i>Reumatología Clínica</i> , <b>2019</b> , 15, 63-68	0.9	0

58	Response to: accuracy of GastroPanel test in detection of atrophic gastritis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2015</b> , 27, 105-6	2.2	o
57	Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients.. <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 823900	4.9	o
56	The ENEIDA registry (Nationwide study on genetic and environmental determinants of inflammatory bowel disease) by GETECCU: Design, monitoring and functions. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2020</b> , 43, 551-558	0.1	o
55	Survey of adherence to treatment in inflammatory bowel disease. ENADEII study. <i>Gastroenterología Y Hepatología</i> , <b>2020</b> , 43, 285-292	0.9	o
54	Quality of care through the eyes of the patient in a Spanish inflammatory bowel disease unit. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2020</b> , 112, 688-693	0.9	o
53	European Registry on the management of Helicobacter pylori infection (Hp-EuReg protocol): The first results of Russian Centers. <i>Russian Journal of Evidence-Based Gastroenterology</i> , <b>2016</b> , 5, 9	0.3	o
52	Colorectal cancer surveillance with chromoendoscopy in inflammatory bowel disease: results from a real-life experience. <i>Scandinavian Journal of Gastroenterology</i> , <b>2021</b> , 56, 806-811	2.4	o
51	Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial.. <i>Therapeutic Advances in Gastroenterology</i> , <b>2019</b> , 12, 1756284819874202	4.7	o
50	Loss of PTPN23 Promotes Proliferation and Epithelial-to-Mesenchymal Transition in Human Intestinal Cancer Cells. <i>Inflammatory Intestinal Diseases</i> , <b>2019</b> , 4, 161-173	2.5	o
49	Tissue Proteomic Approaches to Understand the Pathogenesis of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 1184-1200	4.5	o
48	Attitude facing a patient suffering from Helicobacter pylori infection resistant to a triple therapy. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2003</b> , 95, 220-8, 210-19	0.9	o
47	Evaluation of Natural Language Processing for the Identification of Crohn Disease-Related Variables in Spanish Electronic Health Records: A Validation Study for the PREMONITION-CD Project.. <i>JMIR Medical Informatics</i> , <b>2022</b> , 10, e30345	3.6	o
46	Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi): a multidisciplinary perspective.. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 1-13	5.4	o
45	Current treatment of Helicobacter pylori infection. <i>Medicina Clínica (English Edition)</i> , <b>2017</b> , 148, 20-22	0.3	o
44	Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , <b>2019</b> , 12, 1756284819867848	4.7	o
43	Warnings on the safety of quinolones: Should Helicobacter pylori treatment prescriptions be modified?. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2019</b> , 42, 461-463	0.1	o
42	DOP44 Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multi-centre study from GETECCU. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, S052-S053	1.5	o
41	P526 Survey of adherence to treatment in inflammatory bowel disease: ENADEII STUDY. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, S376-S376	1.5	o

40	P816 Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, S529-S531	1.5
39	Management of acute severe ulcerative colitis in Spain: A nationwide clinical practice survey. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2019</b> , 42, 90-101	0.1
38	P223 Efficacy and safety of tacrolimus in Crohn's disease: a nationwide, multi-centric study from GETECCU. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, S207-S208	1.5
37	P590 An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, S410-S410	1.5
36	Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 1302-3	6.1
35	P573 Frequency and effectiveness of empirical anti-TNF dose intensification in inflammatory bowel disease: an on-going systematic review with meta-analysis. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, S482-S483	1.5
34	Errors in the care of inflammatory bowel disease patients: Errata Study. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2020</b> , 43, 233-239	0.1
33	Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum HpSA and novel ImmunoCard STAT! rapid test) for the diagnosis of Helicobacter pylori infection. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2020</b> , 43, 117-125	0.1
32	P386 Long-term evolution after anti-TNF discontinuation in patients with inflammatory bowel disease (IBD): A multicentre study. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, S359-S360	1.5
31	P156 Differential characteristics of patients with inflammatory bowel disease onset in paediatric age compared with patients diagnosed in adulthood: Results from the CAROUSEL study of GETECCU. <i>Journal of Crohns and Colitis</i> , <b>2018</b> , 12, S174-S176	1.5
30	Update on the management of Helicobacter pylori infection. Position paper from the Catalan Society of Digestology. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2018</b> , 41, 272-280	0.1
29	Letter: anti-TNF in steroid-dependent ulcerative colitis - are the available data enough?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 102	6.1
28	Letter: oral low-dose methotrexate for collagenous colitis - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 98	6.1
27	Letter: management of post-operative Crohn's disease - thiopurines vs adalimumab. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 168-9	6.1
26	P437 Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, S328-S329	1.5
25	Reply to Dr. Katsanos et al.'s letter. <i>Journal of Crohns and Colitis</i> , <b>2013</b> , 7, e23-4	1.5
24	Ustekinumab to treat Crohn's disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2017</b> , 40, 688-698	0.1
23	Accuracy of the Ultra-Rapid Urease Test for diagnosis of Helicobacter pylori infection. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2017</b> , 40, 651-657	0.1

22	Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial. <i>Gastroenterology Y Hepatologia (English Edition)</i> , <b>2017</b> , 40, 658-662	0.1
21	Letter: clarithromycin dose for H. pylori therapy remains unresolved. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 631-2	6.1
20	Letter: mucosal PCR for cytomegalovirus in refractory ulcerative colitis --authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 812-812	6.1
19	Heterogeneity of clinical management of low-grade gastric lymphoma of mucosa-associated lymphoid tissue. An audit of 198 patients in Spain. <i>Gastroenterology Y Hepatologia</i> , <b>2020</b> , 43, 79-86	0.9
18	Epidemiological and clinical characteristics, and response to treatment in 113 patients with microscopic colitis. <i>Gastroenterology Y Hepatologia</i> , <b>2021</b> , 44, 671-679	0.9
17	Assessing aCCess to Investigations in Inflammatory Bowel Disease (ACCID): results from an international survey.. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2021</b> , 33, e837-e842	2.2
16	How to prepare a research proposal in the health sciences. <i>Gastroenterology Y Hepatologia (English Edition)</i> , <b>2021</b> , 44, 730-730	0.1
15	Lack of almagate interference in breath test results for Helicobacter pylori diagnosis (Almatest study). <i>Gastroenterology Y Hepatologia</i> , <b>2021</b> , 44, 628-636	0.9
14	P128 Colorectal cancer surveillance with chromoendoscopy in inflammatory bowel disease: results from a real life experience. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, S201-S201	1.5
13	Epidemiological and clinical characteristics, and response to treatment in 113 patients with microscopic colitis. <i>Gastroenterology Y Hepatologia (English Edition)</i> , <b>2021</b> , 44, 671-671	0.1
12	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on topical therapy in ulcerative colitis. <i>Gastroenterology Y Hepatologia</i> , <b>2020</b> , 43, 97-105	0.9
11	P040 Proteomic characterisation of serum extracellular vesicles in patients with inflammatory bowel diseases: a novel approach for biomarker discovery. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, S152-S153	1.5
10	P086 Identification of constitutive modifications in plasma cells and B lymphocytes in patients with inflammatory bowel disease. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, S177-S178	1.5
9	P475 Association between disease duration and degree of endoscopic improvement in patients with ulcerative colitis treated with tofacitinib. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, S416-S418	1.5
8	Heterogeneity of clinical management of low-grade gastric lymphoma of mucosa-associated lymphoid tissue. An audit of 198 patients in Spain. <i>Gastroenterology Y Hepatologia (English Edition)</i> , <b>2020</b> , 43, 79-86	0.1
7	Errors in the care of inflammatory bowel disease patients: "Errata" Study. <i>Gastroenterology Y Hepatologia</i> , <b>2020</b> , 43, 233-239	0.9
6	DOP19 Urinary metabolome in newly diagnosed treatment-naïve Crohn's Disease patients: Results from the IBDomics study. <i>Journal of Crohns and Colitis</i> , <b>2021</b> , 15, S057-S058	1.5
5	Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure--authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 1020	6.1

4	P013 Novel immunomodulatory role of food bioactive peptide lunasin in the healthy human intestinal mucosa. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, S092-S093	1.5
3	Reply. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2822-2823	6.9
2	Response to the Letter to the Editor: "Response to Infliximab After Loss of Response to Adalimumab in Crohn's Disease". <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, e6	4.5
1	Challenges of independent clinical research. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2021</b> , 44, 599-599	0.1